Free Cash Flow (FCF): $1.33B
The free cash flow (FCF) is $1.33B. It is above its 12-month average by 5.38% ($1.26B).
DGX Free Cash Flow (FCF)
Reported quarterly free cash flow; no daily interpolation.
DGX Quarterly Free Cash Flow Growth (YoY)
Free Cash Flow growth vs the same quarter one year earlier, last 20 quarters.
DGX Average Free Cash Flow (FCF) Chart
DGX Current vs Average Free Cash Flow (FCF) Chart
DGX Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$1.33B
FREE CASH FLOW (FCF) AVG TTM
$1.26B
FREE CASH FLOW (FCF) AVG 3Y
$1.03B
FREE CASH FLOW (FCF) AVG 5Y
$1.29B
FREE CASH FLOW (FCF) AVG 10Y
$1.10B
FREE CASH FLOW (FCF) AVG 15Y
$872.01M
FREE CASH FLOW (FCF) AVG 20Y
$803.30M
CURRENT VS TTM AVG
+5.38%
CURRENT VS 3Y AVG
+28.83%
CURRENT VS 5Y AVG
+2.64%
CURRENT VS 10Y AVG
+20.92%
CURRENT VS 15Y AVG
+52.06%
CURRENT VS 20Y AVG
+65.07%
FCF Analysis
Free Cash Flow (TTM)
$1.33B
FCF Yield
5.74%
Price/FCF
17.4
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The free cash flow (FCF) for DGX stock is $1.33B.
- What is the TTM average free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The TTM average free cash flow (FCF) for DGX stock is $1.26B.
- What is the 3Y average free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The 3Y average free cash flow (FCF) for DGX stock is $1.03B.
- What is the 5Y average free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The 5Y average free cash flow (FCF) for DGX stock is $1.29B.
- What is the 10Y average free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The 10Y average free cash flow (FCF) for DGX stock is $1.10B.
- What is the 15Y average free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The 15Y average free cash flow (FCF) for DGX stock is $872.01M.
- What is the 20Y average free cash flow (FCF) for Quest Diagnostics Incorporated (DGX)?
- The 20Y average free cash flow (FCF) for DGX stock is $803.30M.
DGX Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2026-03-31 | $1.33B |
| 2025-09-30 | $1.39B |
| 2025-03-31 | $1.06B |
| 2024-09-30 | $1.02B |
| 2024-03-31 | $947.00M |
| 2023-09-30 | $596.00M |
| 2023-03-31 | $864.00M |
| 2022-09-30 | $1.46B |
| 2022-03-31 | $1.60B |
| 2021-09-30 | $1.87B |
| 2021-03-31 | $2.07B |
| 2020-09-30 | $1.38B |
| 2020-03-31 | $779.00M |
| 2019-09-30 | $811.00M |
| 2019-03-31 | $938.00M |
| 2018-09-30 | $914.00M |
| 2018-03-31 | $876.00M |
| 2017-09-30 | $858.00M |
| 2017-03-31 | $834.00M |
| 2016-09-30 | $777.00M |
| 2016-03-31 | $647.00M |
| 2015-09-30 | $584.00M |
| 2015-03-31 | $610.00M |
| 2014-09-30 | $550.80M |
| 2014-03-31 | $438.90M |
| 2013-09-30 | $606.60M |
| 2013-03-31 | $871.70M |
| 2012-09-30 | $978.57M |
| 2012-03-31 | $743.57M |
| 2011-09-30 | $710.28M |
| 2011-03-31 | $834.88M |
| 2010-09-30 | $952.62M |
| 2010-03-31 | $796.74M |
| 2009-09-30 | $810.47M |
| 2009-03-31 | $972.54M |
| 2008-09-30 | $839.17M |
| 2008-03-31 | $707.38M |
| 2007-09-30 | $674.81M |
| 2007-03-31 | $671.43M |
| 2006-09-30 | $769.76M |
| 2006-03-31 | $745.14M |
| 2005-09-30 | $591.44M |
| 2005-03-31 | $637.75M |
| 2004-09-30 | $610.40M |
| 2004-03-31 | $532.89M |
| 2003-09-30 | $488.47M |
| 2003-03-31 | $450.41M |
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis